Evidence map›Paper›PMID 37292591›Full record

ArticleResearch square2023

Design, synthesis, and characterization of novel Xc- transport inhibitors: Inhibition of microglial glutamate release and neurotoxicity.

Mariusz Gajewski, Steven Barger

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mariusz GajewskiArkansas Tech University.
Steven BargerUniversity of Arkansas for Medical Sciences.
Arkansas Tech University · USUniversity of Arkansas for Medical Sciences · US

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
Center for Protein Structure and FunctionP30GM103450 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2012 to 2014
$3.2M
Compromised function of a glial glucose transporter in aging and Alzheimer's diseaseR01AG071782 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI BARGER, STEVEN W · 2021 to 2025
$2.1M
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive DiseasesR01AG062254 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI AYYADEVARA, SRINIVAS, SHMOOKLER REIS, ROBERT JOSEPH · 2018 to 2022
$1.9M
NIA NIH HHS R01 AG062254NIA NIH HHS R01 AG071782NIGMS NIH HHS P20 GM103429NIGMS NIH HHS P30 GM103450
6 · The paper itself

Abstract

Neuroinflammation appears to involve some degree of excitotoxicity promulgated by microglia, which release glutamate via the system Xc- cystine-glutamate antiporter. With the aim of mitigating this source of neuronal stress and toxicity, we have developed a panel of inhibitors of the Xc- antiporter. The compounds were based on L-tyrosine, as elements of its structure align with those of glutamate, a primary physiological substrate of the Xc- antiporter. In addition to 3,5-dibromotyrosine, ten compounds were synthesized via amidation of that parent molecule with a selection of acyl halides. These agents were tested for the ability to inhibit release of glutamate from microglia activated with lipopolysaccharide (LPS), an activity exhibited by eight of the compounds. Two of these were further tested for the ability to inhibit death of primary cortical neurons in the presence of activated microglia. While both showed some neuroprotective activity, they were quantitatively distinct with a compound we refer to as "35DBTA7" showing the greatest effi cacy. This agent may hold promise in reducing the neurodegenerative effects of neuroinflammation in conditions such as encephalitis, traumatic brain injury, stroke, or neurodegenerative diseases.

Indexed as

Amino Acid Transport System Xc ProteinCell DeathDrug DiscoveryGlutamic AcidMicrogliaOxidativeStress

Identifiers

PMID37292591
PMCPMC10246248
OpenAlexW4377021437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.